BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2924326)

  • 1. Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans.
    Shani J; Bertram J; Russell C; Dahalan R; Chen DC; Parti R; Ahmadi J; Kempf RA; Kawada TK; Muggia FM
    Cancer Res; 1989 Apr; 49(7):1877-81. PubMed ID: 2924326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
    Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin].
    Nakagawa H; Miyawaki Y; Tokiyoshi K; Tsuruzono K; Yamada M; Kanayama T; Hayakawa T
    No Shinkei Geka; 1994 Jan; 22(1):35-42. PubMed ID: 8295700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
    Civalleri D; Esposito M; De Cian F; Balletto N; Vannozzi MO; Mondini G; Carrabetta S; Bocchio MM
    G Chir; 1997 Apr; 18(4):175-81. PubMed ID: 9303630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body autoradiographic study of the distribution of 195mPt in healthy and tumor-bearing mice treated with labeled cisplatin.
    Bénard P; Desplanches G; Macquet JP; Simon J
    Cancer Treat Rep; 1983 May; 67(5):457-66. PubMed ID: 6406060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
    Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum levels in murine tumor following intraperitoneal administration of cisplatin or paraplatin.
    Douple EB; Totten MD; Spencer F
    NCI Monogr; 1988; (6):129-32. PubMed ID: 3281028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Verify the optimum administration of anticancer agent--cisplatin].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1339-44. PubMed ID: 11681239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
    Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
    Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report].
    Nemoto H; Takeuchi S; Yoshizawa Y; Uemichi O; Sasaya S; Yamaguchi M; Makuuchi M; Midorikawa T; Sanada Y; Kumada K; Takizawa K
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1149-53. PubMed ID: 11525035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of platinum in cancer patients treated with cisplatin at different doses.
    Fracasso ME; Apostoli P; Benoni G; Bonetti A; Griso C; Leone R
    Drugs Exp Clin Res; 1987; 13(6):367-72. PubMed ID: 3652926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
    Júnior AD; Mota LG; Nunan EA; Wainstein AJ; Wainstein AP; Leal AS; Cardoso VN; De Oliveira MC
    Life Sci; 2007 Jan; 80(7):659-64. PubMed ID: 17141809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer.
    Hecquet B; Vennin P; Fournier C; Poissonnier B
    Cancer Res; 1987 Nov; 47(22):6134-7. PubMed ID: 3664513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).
    Stewart DJ; Benjamin RS; Zimmerman S; Caprioli RM; Wallace S; Chuang V; Calvo D; Samuels M; Bonura J; Loo TL
    Cancer Res; 1983 Feb; 43(2):917-20. PubMed ID: 6681533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
    Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
    Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.